Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2016 1
2017 4
2018 1
2019 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: impera s. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, Palumbo GA, Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M; ROMEI study group. Guglielmelli P, et al. Among authors: impera s. Leuk Lymphoma. 2022 Jan;63(1):189-198. doi: 10.1080/10428194.2021.1969388. Epub 2021 Sep 15. Leuk Lymphoma. 2022. PMID: 34521299
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. Pennisi MS, et al. Among authors: impera s. Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019. Front Oncol. 2019. PMID: 31456947 Free PMC article.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: impera s. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
Quality of life and physicians' perception in myelodysplastic syndromes.
Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Oliva EN, et al. Among authors: impera s. Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25. Am J Blood Res. 2012. PMID: 22762033 Free PMC article.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M. Castagnetti F, et al. Among authors: impera s. Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18. Am J Hematol. 2017. PMID: 27770583 Free article.
"On-demand" treatment with Thrombopoietin mimetics as "bridge to recovery" from chemotherapy in chronic immune thrombocytopenia patients with cancer. A single centre experience in nine patients.
Spina P, Impera S, Todaro AM, Salerno M, Floridia PM, Castagna F, Consoli U. Spina P, et al. Among authors: impera s. Br J Haematol. 2018 May;181(3):400-403. doi: 10.1111/bjh.14605. Epub 2017 May 3. Br J Haematol. 2018. PMID: 28466471 Free article. No abstract available.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R. Oliva EN, et al. Among authors: impera s. Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3. Lancet Haematol. 2017. PMID: 28162984 Clinical Trial.
11 results